The Indian pharmaceutical industry is estimated to be worth USD 21.5 billion as of 2009-10 and is expected to grow at a CAGR of 16-18 percent during 2009-2010 to 2014-15 to reach USD 43-46 billion.




There is a huge opportunity for Indian generics players with many blockbuster drugs going off-patent in the next five years. The sub-sectors such as biopharmaceuticals and Contract Research and Manufacturing Services (CRAMS) are expected to become the new frontiers of growth.  India is increasingly being looked at as a preferred destination for clinical trials and other services.


With such high growth predicted for the industry, the challenges the industry will have to overcome will be at a global level.


To be decided

Utkarsh Palnitkar
Head of Pharmaceuticals

How can we help

KPMG’s industry-focused professionals understand the pharmaceutical sector and can assist you in recognizing and capitalizing on the opportunities that exist.  Our professionals offer a powerful blend of industry insight and proven credentials to help you and your organization successfully achieve its mission and objectives.
Our audit, tax and advisory practices offer a bouquet of solutions to the pharmaceutical industry. A few of these solutions are listed below:



Tax Advisory and Compliance Services

  • Corporate Tax and Regulatory Services
  • Transfer Pricing Services
  • Indirect Tax Services including Tax Outsourcing
  • International Executive Services
  • M&A Tax Services
  • Others



  • M&A Advisory
  • Financing Advisory
  • Valuation Services
  • Due Diligence Services
  • Risk Management Services
  • Internal Audit Services
  • Fraud & Misconduct Services
  • Forensic Technology Services
  • Business Plan Formulation and Implementation
  • Market Entry and Expansion Strategy
  • Others